ARKG vs VCIT
ARK Genomic Revolution ETF vs Vanguard Intermediate-Term Corporate Bond ETF
ARKG$43.17
ARK Genomic Revolution ETF
Companies advancing genomics and molecular biology.
Expense: 0.75%Yield: 0.00%
VCIT$82.08
Vanguard Intermediate-Term Corporate Bond ETF
Intermediate-term investment-grade corporate bonds.
Expense: 0.03%Yield: 4.78%
Quick take
- • VCIT has the lower expense ratio at 0.03% vs 0.75% for ARKG.
- • VCIT pays a higher dividend yield (4.78%).
Side-by-side metrics
| Metric | ARKG | VCIT |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.03% |
Dividend yield Trailing 12-month yield. | 0.00% | 4.78% |
AUM Assets under management — bigger funds are typically more liquid. | $1.73B | $69.44B |
YTD return | 44.53% | 0.05% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.38 | 1.07 |
P/E ratio | — | — |
Last price | $43.17 | $82.08 |
Inception | — | — |
Issuer | ARK | Vanguard |
ARKG top holdings
Top holdings · ARKG
| TWST | Twist Bioscience Corp | 9.15% |
| TEM | Tempus AI Inc Class A common stock | 7.64% |
| ABSI | Absci Corp | 7.01% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 7.00% |
| CRSP | CRISPR Therapeutics AG | 6.56% |
| PSNL | Personalis Inc | 6.19% |
| BEAM | Beam Therapeutics Inc | 4.34% |
| GH | Guardant Health Inc | 4.28% |
| NTRA | Natera Inc | 4.11% |
| ILMN | Illumina Inc | 3.98% |
Sector breakdown · ARKG
Healthcare100.0%
VCIT top holdings
Holdings data unavailable for VCIT.
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About VCIT
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) is Intermediate-term investment-grade corporate bonds. Managed by Vanguard, the fund carries $69.4B in assets under management, an expense ratio of 0.03%, a dividend yield of 4.78%.